Monte Rosa Therapeutics (GLUE) Cash & Current Investments (2023 - 2025)
Historic Cash & Current Investments for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $401.6 million.
- Monte Rosa Therapeutics' Cash & Current Investments rose 21983.04% to $401.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $401.6 million, marking a year-over-year increase of 21983.04%. This contributed to the annual value of $381.0 million for FY2024, which is 6113.91% up from last year.
- As of Q3 2025, Monte Rosa Therapeutics' Cash & Current Investments stood at $401.6 million, which was up 21983.04% from $300.9 million recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Cash & Current Investments ranged from a high of $401.6 million in Q3 2025 and a low of $47.0 million during Q2 2023
- In the last 3 years, Monte Rosa Therapeutics' Cash & Current Investments had a median value of $125.6 million in 2024 and averaged $195.3 million.
- In the last 5 years, Monte Rosa Therapeutics' Cash & Current Investments soared by 6113.91% in 2024 and then skyrocketed by 23591.41% in 2025.
- Quarter analysis of 3 years shows Monte Rosa Therapeutics' Cash & Current Investments stood at $236.4 million in 2023, then soared by 61.14% to $381.0 million in 2024, then grew by 5.42% to $401.6 million in 2025.
- Its Cash & Current Investments was $401.6 million in Q3 2025, compared to $300.9 million in Q2 2025 and $335.1 million in Q1 2025.